Pandemic Darlings The pandemic economy, in original documents
Home Source documents Vir Biotechnology, Inc. Form 4 (June 8, 2022) — SATO VICKI LSearch ⌕

Vir Biotechnology, Inc. Form 4 (June 8, 2022) — SATO VICKI L

Summary

This Form 4 reports sales of Vir Biotechnology, Inc. (VIR) common stock on 06/08/2022 by director Vicki L. Sato: 17,415 shares at a weighted average price of $25.8238 and 500 shares at $26.51. The footnotes state the sales were effected under a Rule 10b5-1 trading plan the reporting person adopted on March 28, 2022, and that the first block sold at prices from $25.47 to $26.46. Direct ownership after the sales was 1,488,579 shares. The form is signed /s/ Howard Horn, Attorney-in-Fact, dated 06/09/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Vir Biotechnology, Inc. Form 4 (June 8, 2022) — SATO VICKI L.” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-vir-4-filed2022-06-09-0001209191-22-035428-6ceb401617/, SHA-256 e390051311529da84e200d42a380e129b9874f8d785cc432532196e1bb83560f.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * SATO VICKI L (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | SATO VICKI L | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 06/08/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 06/08/2022 | S (1) | 17,415 | D | $ 25.8238 (2) | 1,489,079 | D
Common Stock | 06/08/2022 | S (1) | 500 | D | $ 26.51 | 1,488,579 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 to $26.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Remarks:
/s/ Howard Horn, Attorney-in-Fact | 06/09/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_VIR_4_filed2022-06-09_0001209191-22-035428.xml
Size
16,279 bytes
SHA-256
e390051311529da84e200d42a380e129b9874f8d785cc432532196e1bb83560f
Our copy
SEC_VIR_4_filed2022-06-09_0001209191-22-035428.xml
Original
www.sec.gov
Back to top